Posts by: Alice Melão

Alice Melão

May 7, 2018

Arthritis Medication May Prevent GvHD, Side Effect of Stem Cell Transplants, Mouse Study Suggests

News

Baricitinib, a medicine approved in Europe for the treatment for rheumatoid arthritis, both prevented and reverted a life-threatening complication of stem cell transplants called graft-versus-host disease, a study in mice suggests. ... Read more

April 26, 2018April 26, 2018

Nearly Half of NHL Patients in Phase 1 Trial Respond to ALT-803, Rituxan Combo, Results Show

News

A combination of Rituxan (rituximab) and the experimental agent ALT-803 leads to a response rate of 48% in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma, according to preliminary data from a ... Read more

April 11, 2018

Tenalisib Receives FDA Orphan Drug Status for Treatment of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration has granted orphan drug status to investigational therapy tenalisib (RP6530) for the treatment of cutaneous T-cell lymphoma, Rhizen Pharmaceuticals announced. In December, the therapy also received ... Read more

April 9, 2018

First Patient Dosed in Phase 3 Trial of Denovo’s DB102 Plus Chemo for High-risk DLBCL

News

A pivotal Phase 3 trial evaluating Denovo Biopharma‘s investigational therapy DB102 (enzastaurin) as an add-on to standard chemotherapy for high-risk diffuse large B-cell lymphoma (DLBCL) has started dosing patients. The ... Read more

April 6, 2018

Bioniz Recruiting Patients for Phase 1/2 Trial of Its Leukemia and Lymphoma Therapy

News

Bioniz Therapeutics is recruiting certain types of leukemia and lymphoma patients for a Phase 1/2 clinical trial of its cancer therapy BNZ-1. The company is seeking people with large granular ... Read more

April 3, 2018

Phase 2 Study of DPX-Survivac Combo Doses First Lymphoma Patient

News

A Phase 2 trial testing Immunovaccine‘s combination of DPX-Survivac with chemotherapy and an immune checkpoint inhibitor in diffuse large B-cell lymphoma (DLBCL) has dosed its first participant. The trial is supported by ... Read more

March 20, 2018March 20, 2018

Rich’s RP-323 Shows Activity Against Hodgkin’s Lymphoma in Phase 1 Trial

News

Experimental therapy RP-323 has shown anticancer activity against Hodgkin’s lymphoma in a Phase 1 trial. Its developer, Rich Pharmaceuticals, is now planning to evaluate the therapy in human clinical trials for the ... Read more

March 14, 2018March 14, 2018

G100-Keytruda Combo Shows Higher Response in Follicular Lymphoma Patients in Phase 2 Trial

News

Data from a Phase 2 clinical trial showed that combining Immune Design‘s experimental immunotherapy G100 with fractioned, low-dose radiation and Keytruda (pembrolizumab) leads to higher response rates in follicular lymphoma patients, the company announced. The ... Read more

March 12, 2018March 12, 2018

Lymphoma, Breast Cancer Patients Have Higher Risk of Heart Failure, Study Shows

News

Breast cancer and lymphoma patients and survivors are 3.6 times more likely to develop heart failure than patients who did not have cancer, a study by researchers at the ... Read more

March 8, 2018March 8, 2018

Constellation’s Epigenetic Inhibitors Show Early Signs of Activity in Advanced Lymphoma Patients

News

Two investigative compounds targeting epigenetic DNA modification have shown encouraging preliminary activity in B-cell lymphoma patients, according to results from two Phase 1 trials. The inhibitors, called CPI-1205 and CPI-0610, were found ... Read more

Pin It on Pinterest